scispace - formally typeset
Search or ask a question
Author

Zhi-Wen Fang

Bio: Zhi-Wen Fang is an academic researcher from Harbin Medical University. The author has contributed to research in topics: Pharmacokinetics & Acute promyelocytic leukemia. The author has an hindex of 1, co-authored 1 publications receiving 1345 citations.

Papers
More filters
Journal ArticleDOI
01 May 1997-Blood
TL;DR: As2O3 treatment is an effective and relatively safe drug in APL patients refractory to ATRA and conventional chemotherapy, and Pharmacokinetic studies showed that after a peak level of 5.54 micromol/L, plasma arsenic was rapidly eliminated, and the continuous administration of As2O2 did not alter its pharmacokinetic behaviors.

1,398 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: ROS stress in cancer cells is reviewed, its underlying mechanisms and relationship with mitochondrial malfunction and alteration in drug sensitivity are reviewed, and new therapeutic strategies that take advantage of increased ROS in cancer Cells to enhance therapeutic activity and selectivity are suggested.

1,823 citations

Journal ArticleDOI
TL;DR: The role of these four ABC transporter proteins in protecting tissues from a variety of toxicants is discussed and species variations in substrate specificity and tissue distribution of these transporters are addressed since these properties have implications for in vivo models of toxicity used for drug discovery and development.

1,327 citations

Journal ArticleDOI
TL;DR: Low doses of arsenic trioxide can induce complete remissions in patients with APL who have relapsed and the clinical response is associated with incomplete cytodifferentiation and the induction of apoptosis with caspase activation in leukemic cells.
Abstract: Background Two reports from China have suggested that arsenic trioxide can induce complete remissions in patients with acute promyelocytic leukemia (APL). We evaluated this drug in patients with APL in an attempt to elucidate its mechanism of action. Methods Twelve patients with APL who had relapsed after extensive prior therapy were treated with arsenic trioxide at doses ranging from 0.06 to 0.2 mg per kilogram of body weight per day until visible leukemic cells were eliminated from the bone marrow. Bone marrow mononuclear cells were serially monitored by flow cytometry for immunophenotype, fluorescence in situ hybridization, reverse-transcription–polymerase-chain-reaction (RT-PCR) assay for PML–RAR-α fusion transcripts, and Western blot analysis for expression of the apoptosis-associated proteins caspases 1, 2, and 3. Results Of the 12 patients studied, 11 had a complete remission after treatment that lasted from 12 to 39 days (range of cumulative doses, 160 to 515 mg). Adverse effects were relatively m...

1,210 citations

Journal ArticleDOI
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Abstract: Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. Methods

1,184 citations

Journal ArticleDOI
01 Mar 2008-Blood
TL;DR: The history of introduction of ATRA and ATO into clinical use and the mechanistic studies in understanding this model of cancer targeted therapy are reviewed.

1,121 citations